FamHis, Inc. announces the completion and worldwide release of their next-generation family health history platform FamGenix. The free patient mobile app was soft-launched in November, 2019 and the provider portal for clinicians was released last month. The platform facilitates a telemedicine-based approach to gathering family health histories, saving time and improving accuracy. In line with FamHis’ commitment to patient data security, servers have been launched in the US and Europe, and are planned for Canada and Australia next month.
Recommended AI News: S&P Global Market Intelligence Becomes Exclusive Provider of Citigroup Aftermarket Research
FamGenix revolutionizes collection of family health history by putting patients in control of their own data. Patients engage with other family members through a unique feature called FamShare, allowing for secure exchange of data and a more accurate family history. Each family member controls their own record and privacy settings. Important health information, like genetic test results, can be easily communicated with other family members via the app, facilitating cascade screening.
“With 25 years in the industry, I’ve seen firsthand the benefits of an accurate family health history and the effect it has on decision making for healthcare providers and their patients,” said Michael Brammer, Founder and CEO of FamHis, Inc. “But the idea that it’s something to address only when patients are facing a health crisis, is short-sighted. FamGenix is much more than a simple screening tool and is the first of its kind to empower patients to own and maintain their own family health history, indefinitely. Preventative healthcare is the future of medicine and it begins with family history.”
Recommended AI News: Developer-Centric Application Security Company StackHawk Announces Its General Availability Launch
Healthcare providers can review patient data, including an auto-generated pedigree in the provider portal. The system screens patients and identifies high-risk individuals who meet criteria for further genetic counseling or testing based on NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) from the National Comprehensive Cancer Network® (NCCN®). Multiple integrated cancer risk assessment models, including BOADICEA, calculate a patient’s lifetime cancer risk. Standard or custom questionnaires allow for capturing any condition (not limited to cancer) or other data needed for clinical or research purposes.
There is a white-label option for healthcare providers who want to brand the app as their own in the app stores. FamHis signed their first white-label license with a prestigious cancer center and has pilots planned in several countries.
Recommended AI News: S&P Global Market Intelligence Becomes Exclusive Provider of Citigroup Aftermarket Research
Comments are closed, but trackbacks and pingbacks are open.